MAIA Biotechnology to Acquire Private Company
Ticker: MAIA · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1878313
Sentiment: neutral
Topics: acquisition, corporate-action
Related Tickers: MAIA
TL;DR
MAIA Bio buying a private company, deal expected Q4 2025.
AI Summary
MAIA Biotechnology, Inc. announced on September 7, 2025, that it has entered into a definitive agreement to acquire all outstanding equity interests of a privately held company. The acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions. This strategic move aims to expand MAIA's pipeline and market presence.
Why It Matters
This acquisition could significantly expand MAIA Biotechnology's product pipeline and market reach, potentially leading to future growth and innovation in the biotechnology sector.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overvaluation, and the possibility that the acquired company's assets may not perform as expected.
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- September 7, 2025 (date) — Date of earliest event reported
- fourth quarter of 2025 (date) — Expected closing of acquisition
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is to report under Item 7.01 Regulation FD Disclosure that MAIA Biotechnology, Inc. has entered into a definitive agreement to acquire a privately held company.
When is the acquisition expected to be completed?
The acquisition is expected to close in the fourth quarter of 2025.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
What is the trading symbol and exchange for MAIA Biotechnology, Inc. common stock?
The trading symbol is MAIA, and it is registered on the NYSE American.
What is the principal executive office address for MAIA Biotechnology, Inc.?
The principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-09-08 06:11:22
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 1KB
- ex99-1_001.jpg (GRAPHIC) — 12956KB
- 0001493152-25-012769.txt ( ) — 18024KB
- maia-20250907.xsd (EX-101.SCH) — 3KB
- maia-20250907_lab.xml (EX-101.LAB) — 33KB
- maia-20250907_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 8, 2025 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer -4-